ISIvan Stamenkovic

Ivan Stamenkovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ivan Stamenkovic has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Paolo Provero

    14 shared publications
  • Igor Letovanec

    Department of Histopathology, Central Institute, Valais Hospital, Sion, Switzerland

    8 shared publications
  • Nicolo Riggi

    CHU Vaudois, Lausanne, Switzerland

    8 shared publications
  • Carlo Fusco

    Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

    7 shared publications
  • Michalina Janiszewska

    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA

    7 shared publications
  • Patricia Martin

    Experimental Pathology Service, Centre Hospitalier Universitaire Vaudois and Department of Research and Education, University of Lausanne, Lausanne, Switzerland

    7 shared publications

Latest Publications

  • Open Access

    The MD-PhD programme: a key investment for academic medical centres

    by Ivan Stamenkovic, Lucia Mazzolai

  • Open Access

    CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas

    by Arnaud Bakaric, Luisa Cironi, Viviane Praz, Rajendran Sanalkumar, Liliane C. Broye, Kerria Favre-Bulle, Igor Letovanec, Antonia Digklia, Raffaele Renella, Ivan Stamenkovic, et al.

    CIC-DUX4-rearranged sarcoma (CDS) is a rare and aggressive soft tissue tumor that occurs most frequently in young adults. The key oncogenic driver of this disease is the expression of the CIC-DUX4 fusion protein as a result of chromosomal rearrangements. CIC-DUX4 displays chromatin binding properties, and is therefore believed to function as an aberrant transcription factor. However, the chromatin remodeling events induced by CIC-DUX4 are not well understood, limiting our ability to identify new mechanism-based therapeutic strategies for these patients. Here, we generated a genome-wide profile of CIC-DUX4 DNA occupancy and associated chromatin states in human CDS cell models and primary tumors. Combining chromatin profiling, proximity ligation assays, as well as genetic and pharmacological perturbations, we show that CIC-DUX4 operates as a potent transcriptional activator at its binding sites. This property is in contrast with the repressive function of the wild-type CIC protein, and is mainly mediated through the direct interaction of CIC-DUX4 with the acetyltransferase p300. In keeping with this, we show p300 to be essential for CDS tumor cell proliferation; additionally, we find its pharmacological inhibition to significantly impact tumor growth in vitro and in vivo. Taken together, our study elucidates the mechanisms underpinning CIC-DUX4-mediated transcriptional regulation.


  • Open Access

    Necrotic debris and STING exert therapeutically relevant effects on tumor cholesterol homeostasis

    by Sampath Katakam, Santosh Anand, Patricia Martin, Nicolo Riggi, Ivan Stamenkovic

    Malignant tumors commonly display necrosis, which invariably triggers an inflammatory response that supports tumor growth. However, the effect on tumor cells of necrotic debris, or damage-associated molecular patterns (DAMPs) released by dying cells is unknown. Here, we addressed the effect of DAMPs on primary Ewing sarcoma (EwS) cells and cell lines grown in 3D (spheroids) and 2D culture. We show that DAMPs promote the growth of EwS spheroids but not 2D cultures and that the underlying mechanism implicates an increase in cholesterol load in spheroids. In contrast, stimulation of the nucleic acid sensor signaling platform STING by its ligand cyclic GMP-AMP decreases the tumor cell cholesterol load and reduces their tumor initiating ability. Overexpression of STING or stimulation with cyclic GMP-AMP opposes the growth stimulatory effect of DAMPs and synergizes with the cholesterol synthesis inhibitor simvastatin to inhibit tumor growth. Our observations show that modulation of cholesterol homeostasis is a major effect of necrotic cell debris and STING and suggest that combining STING agonists with statins may help control tumor growth.


  • Open Access

    A live single-cell reporter assay links intratumor heterogeneity to metastatic proclivity in Ewing sarcoma

    by Tugba Keskin, Beatrice Rucci, Sandrine Cornaz-Buros, Patricia Martin, Carlo Fusco, Liliane Broye, Katarina Cisarova, Elizabeth M. Perez, Igor Letovanec, Stefano La Rosa, et al.

    Targeting of the most aggressive tumor cell subpopulations is key for effective management of most solid malignancies. However, the metastable nature of tumor heterogeneity, which allows cells to transition between strong and weak tumorigenic phenotypes, and the lack of reliable markers of tumor-promoting properties hamper identification of the most relevant cells. To overcome these obstacles, we designed a functional microRNA (miR)–based live-cell reporter assay to identify highly tumorigenic cells in xenotransplants of primary Ewing sarcoma (EwS) 3D cultures. Leveraging the inverse relationship between cell pluripotency and miR-145 expression, we successfully separated highly tumorigenic, metastasis-prone (miR-145low) cells from poorly tumorigenic, nonmetastatic (miR-145high) counterparts. Gene expression and functional studies of the two cell populations identified the EPHB2 receptor as a prognostic biomarker in patients with EwS and a major promoter of metastasis. Our study provides a simple and powerful means to identify and isolate tumor cells that display aggressive behavior.


    • 15 April 2021
      • Vol. 384  (15) , 1477-1478

    Ewing's Sarcoma Reply

    by Nicolo Riggi, Mario L. Suva, Ivan Stamenkovic

  • Open Access

    The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies

    by Gaylor Boulay, Luisa Cironi, Sara P Garcia, Shruthi Rengarajan, Yu-Hang Xing, Lukuo Lee, Mary E Awad, Beverly Naigles, Sowmya Iyer, Liliane C Broye, et al.

    Synovial sarcoma (SyS) is an aggressive mesenchymal malignancy invariably associated with the chromosomal translocation t(X:18; p11:q11), which results in the in-frame fusion of the BAF complex gene SS18 to one of three SSX genes. Fusion of SS18 to SSX generates an aberrant transcriptional regulator, which, in permissive cells, drives tumor development by initiating major chromatin remodeling events that disrupt the balance between BAF-mediated gene activation and polycomb-dependent repression. Here, we developed SyS organoids and performed genome-wide epigenomic profiling of these models and mesenchymal precursors to define SyS-specific chromatin remodeling mechanisms and dependencies. We show that SS18-SSX induces broad BAF domains at its binding sites, which oppose polycomb repressor complex (PRC) 2 activity, while facilitating recruitment of a non-canonical (nc)PRC1 variant. Along with the uncoupling of polycomb complexes, we observed H3K27me3 eviction, H2AK119ub deposition and the establishment of de novo active regulatory elements that drive SyS identity. These alterations are completely reversible upon SS18-SSX depletion and are associated with vulnerability to USP7 loss, a core member of ncPRC1.1. Using the power of primary tumor organoids, our work helps define the mechanisms of epigenetic dysregulation on which SyS cells are dependent.


  • Open Access

    LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma

    by Tugba Keskin, Arnaud Bakaric, Patricia Waszyk, Gaylor Boulay, Matteo Torsello, Sandrine Cornaz-Buros, Nadja Chevalier, Thibaud Geiser, Patricia Martin, Angela Volorio, et al.


  • Open Access

    LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma

    by Tugba Keskin, Arnaud Bakaric, Patricia Waszyk, Gaylor Boulay, Matteo Torsello, Sandrine Cornaz-Buros, Nadja Chevalier, Thibaud Geiser, Patricia Martin, Angela Volorio, et al.


  • Open Access

    Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression

    by Sabine Galland, Ivan Stamenkovic

    Mesenchymal stem or stromal cells (MSCs) are pluripotent cells implicated in a broad range of physiological events, including organogenesis and maintenance of tissue homeostasis as well as tissue regeneration and repair. Because their current definition is somewhat loose – based primarily on their ability to differentiate into a variety of mesenchymal tissues, adhere to plastic, and express, or lack, a handful of cell surface markers – MSCs likely encompass several subpopulations, which may have diverse properties. Their diversity may explain, at least in part, the pleiotropic functions that they display in different physiological and pathological settings. In the context of tissue injury, MSCs can respectively promote and attenuate inflammation during the early and late phases of tissue repair. They may thereby act as sensors of the inflammatory response and secrete mediators that boost or temper the response as required by the stage of the reparatory and regenerative process. MSCs are also implicated in regulating tumor development, in which they are increasingly recognized to play a complex role. Thus, MSCs can both promote and constrain tumor progression by directly affecting tumor cells via secreted mediators and cell–cell interactions and by modulating the innate and adaptive immune response. This review summarizes our current understanding of MSC involvement in tumor development and highlights the mechanistic underpinnings of their implication in tumor growth and progression. © 2020 Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.


  • Open Access

    Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis

    by Giulia Fregni, Mathieu Quinodoz, Emely Möller, Joanna Vuille, Sabine Galland, Carlo Fusco, Patricia Martin, Igor Letovanec, Paolo Provero, Carlo Rivolta, et al.